<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01815073</url>
  </required_header>
  <id_info>
    <org_study_id>NCT02049715</org_study_id>
    <nct_id>NCT01815073</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine</brief_title>
  <official_title>A Study to Evaluate the Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changchun Keygen Biological Products Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangdong Provincial Institute of Biological Products And Materia Medica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Changchun Keygen Biological Products Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe the occurrence of adverse events and seroconversion
      rate, geometric mean titres (GMTs) of live attenuated varicella vaccine，live attenuated JE
      vaccine and live attenuated varicella vaccine combined with live attenuated JE vaccine,
      respectively.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion rate and GMTs for live attenuated varicella vaccine, live attenuated JE vaccine and live attenuated varicella vaccine combined with live attenuated JE vaccine, respectively.</measure>
    <time_frame>35-42 days after vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events.</measure>
    <time_frame>within 30 days after each vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">497</enrollment>
  <condition>Japanese Encephalitis</condition>
  <condition>Chickenpox</condition>
  <arm_group>
    <arm_group_label>Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>use the left arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Live Attenuated Varicella Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>use the right arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Live Attenuated JE Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>use the right arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine</intervention_name>
    <arm_group_label>Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Live Attenuated Varicella Vaccine</intervention_name>
    <arm_group_label>Live Attenuated Varicella Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>live attenuated JE vaccine</intervention_name>
    <arm_group_label>Live Attenuated JE Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parent/legal acceptable representative is willing and able to understand the protocol
             requirements and provide informed consent

          -  Participant is aged ≥ 1 year to ≤ 3 years

          -  Participant without previous history of chickenpox, zoster and epidemic encephalitis B

          -  Subject and parent/guardian able to attend all scheduled visits and comply with all
             trial procedures

          -  Body temperature ≤ 37.5℃

        Exclusion Criteria:

          -  Known allergy to any constituent of the vaccine

          -  Known acute illness, severe chronic disease, acute exacerbation of chronic disease and
             fever

          -  Known or suspected impairment of immunologic function, or receipt of immunosuppressive
             therapy or immunoglobulin since birth

          -  Reported the history of allergies, convulsions, epilepsy, mental illness and brain
             disease and clear serious systemic reaction

          -  Failed to the Expanded Programme on Immunization(EPI)

          -  Receipt of any vaccine in the 4 weeks preceding the trial vaccination

          -  Plan to receive any vaccine in the 4 weeks following the trial vaccination

          -  Known bleeding disorder

          -  Receipt of whole blood, blood plasma or immunoglobulin in the 5 months preceding the
             trial vaccination

          -  Reported the history of acute illness had need systemic antibiotics or anti-viral
             treatment of infections in the 7 days preceding the trial vaccination

          -  An acute illness with or without fever (temperature ≥ 38.0℃) in the 3 days preceding
             enrollment in the trial

          -  Participation in any other interventional clinical trial

          -  Any condition which, in the opinion of the investigator, would pose a health risk to
             the subject or interfere with the vaccine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>3 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zheng Huizhen, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong Center for Disease Prevention and Control</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guangzhou Haizhu District Center for Disease Control and Prevention</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2013</study_first_submitted>
  <study_first_submitted_qc>March 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2013</study_first_posted>
  <last_update_submitted>February 20, 2014</last_update_submitted>
  <last_update_submitted_qc>February 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Encephalitis, Japanese</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 24, 2015</submitted>
    <returned>December 30, 2015</returned>
    <submitted>March 15, 2016</submitted>
    <returned>April 13, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

